Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Recent & Breaking News (NDAQ:AZN)

AstraZeneca Launches Signature STEM Program to Empower Students to Live Healthier Lives and Inspire Future Scientists

Business Wire October 7, 2019

FASENRA® (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen(TM)

Business Wire October 4, 2019

LYNPARZA (olaparib) More Than Doubled the Time Without Radiographic Disease Progression in Patients With BRCA1/2- or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

Business Wire September 30, 2019

TAGRISSO Is the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years

Business Wire September 28, 2019

LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer

Business Wire September 28, 2019

BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial

Business Wire September 26, 2019

FDA Grants Fast Track Designation for FARXIGA in Heart Failure

Business Wire September 16, 2019

IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer

Business Wire September 9, 2019

BRILINTA Reduced the Risk of Cardiovascular Events in Patients With Coronary Artery Disease and Type 2 Diabetes in Phase III THEMIS Trial

Business Wire September 1, 2019

Detailed Results from Phase III DAPA-HF Trial Showed FARXIGA Significantly Reduced Both the Incidence of Cardiovascular Death and the Worsening of Heart Failure

Business Wire September 1, 2019

PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease

Business Wire August 28, 2019

FDA Grants Fast Track Designation for FARXIGA in Chronic Kidney Disease

Business Wire August 27, 2019

FARXIGA Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure

Business Wire August 20, 2019

CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia

Business Wire August 14, 2019

LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer

Business Wire August 14, 2019

TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer

Business Wire August 9, 2019

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

GlobeNewswire August 7, 2019

LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

Business Wire August 7, 2019

BioCardia Signs Exclusive Development Agreement With AstraZeneca

GlobeNewswire July 25, 2019

IMFINZI® (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer

Business Wire July 22, 2019